EQH Stock Analysis: Axa Equitable Holdings | NYSE
Asset Management | NYSE, USA | Market Cap: 13.867m USD | 12M Return: -3.2% | US29452E1010 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 137M
EPS Trend: 82.8%
Qual. Beats: 0
Rev. Trend: 26.2%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 8.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Equitable Holdings, Inc. (EQH) is a diversified financial services company headquartered in New York, operating through six business segments: Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. The company primarily serves affluent and high-net-worth individuals through variable annuity products, while also providing retirement services to plans sponsored by educational entities, municipalities, non-profit organizations, and small-to-medium-sized businesses. Its offerings span investment management, life insurance (including VUL, COLI, IUL, and term life), employee benefits, and advisory/financial planning services, with the Legacy segment housing its capital-intensive fixed-rate GMxB business. The company was founded in 1859, was formerly known as AXA Equitable Holdings, Inc., and adopted its current name in January 2020.
As a large-cap U.S. financials company listed on the NYSE, EQH operates within the diversified financial services sub-industry, generating revenue through a mix of insurance premiums, asset-based fees, and advisory commissions. Variable annuities, a core product for the firm, are hybrid insurance-investment contracts that have faced increased regulatory scrutiny in recent years regarding living and death benefit guarantees.
- Interest rate path drives spread income and hedging costs
- Equity market gains lift Asset Management AUM and fees
- Legacy GMxB runoff releases capital for shareholder returns
| Net Income: -926.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: -1.04k% < 20% (prev -506.9%; Δ -531.4% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.43b > Net Income -926.0m |
| Current Ratio: 0.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (278.3m) vs 12m ago -8.21% < -2% |
| Gross Margin: 72.67% > 18% (prev 66.96%; Δ 5.71% > 0.5%) |
| Asset Turnover: 3.33% > 50% (prev 4.24%; Δ -0.92% > 0%) |
| Interest Coverage Ratio: -1.70 > 6 (EBIT TTM -384.0m / Interest Expense TTM 226.0m) |
| A: -0.33 (Total Current Assets 40.4b - Total Current Liabilities 151b) / Total Assets 335b |
| B: 0.02 (Retained Earnings 8.23b / Total Assets 335b) |
| C: -0.00 (EBIT TTM -384.0m / Avg Total Assets 319b) |
| D: -0.00 (Book Value of Equity -785.0m / Total Liabilities 333b) |
| Altman-Z'' = -2.09 = D |
| DSRI: 2.50 (Receivables 23.0b/11.2b, Revenue 10.6b/12.9b) |
| GMI: 0.92 (GM 66.96% / 72.67%) |
| AQI: 1.11 (AQ_t 0.88 / AQ_t-1 0.79) |
| SGI: 0.83 (Revenue 10.6b / 12.9b) |
| TATA: -0.01 (NI -926.0m - CFO 1.43b) / TA 335b) |
| Beneish M = -1.93 (Cap -4..+1) = B |
As of August 22, 2026, the stock is trading at USD 48.90 with a total of 1,860,653 shares traded. Over the past week, the price has changed by -7.89%, over one month by +1.57%, over three months by +16.58% and over the past year by -3.19%.
Current recommended Stop Loss: 45.60 (which is 6.7% or 2.2 ATR below the current price).
Axa Equitable Holdings has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy EQH.
- StrongBuy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 61.6 | 25.9% |
P/E Forward = 4.5851
P/S = 1.3058
P/B = 164.1395
Revenue TTM = 10.6b USD
EBIT TTM = -384.0m USD
EBITDA TTM = 493.0m USD
Long Term Debt = 6.97b USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last fiscal year)
Debt = 6.99b USD (corrected: LT Debt 6.97b + ST Debt 25.0m)
Net Debt = -51.6b USD (calculated: Debt 6.99b - CCE 58.6b)
Enterprise Value = 13.9b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -1.70 (Ebit TTM -384.0m / Interest Expense TTM 226.0m)
EV/FCF = 9.94x (Enterprise Value 13.9b / FCF TTM 1.40b)
FCF Yield = 10.06% (FCF TTM 1.40b / Enterprise Value 13.9b)
FCF Margin = 13.14% (FCF TTM 1.40b / Revenue TTM 10.6b)
Net Margin = -8.72% (Net Income TTM -926.0m / Revenue TTM 10.6b)
Gross Margin = 72.67% ((Revenue TTM 10.6b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 74.67% (prev 90.69%)
Tobins Q-Ratio = 0.04 (Enterprise Value 13.9b / Total Assets 335b)
Interest Expense / Debt = 3.23% (Interest Expense 226.0m / Debt 6.99b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -303.4m (EBIT -384.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.27 (Total Current Assets 40.4b / Total Current Liabilities 151b)
Debt / Equity = -8.91 (negative equity) (Debt 6.99b / totalStockholderEquity, last quarter -785.0m)
Debt / EBITDA = -104.7 (out of range, set to none) (Net Debt -51.6b / EBITDA 493.0m)
Debt / FCF = -36.99 (Net Debt -51.6b / FCF TTM 1.40b)
Total Stockholder Equity = -109.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.29% (Net Income -926.0m / Total Assets 335b)
RoE = 845.7% (negative equity) (Net Income TTM -926.0m / Total Stockholder Equity -109.5m)
RoCE = -5.60% (EBIT -384.0m / Capital Employed (Equity -109.5m + L.T.Debt 6.97b))
RoIC = -0.17% (negative operating profit) (NOPAT -303.4m / Invested Capital 183b)
WACC = 7.60% (E(13.9b)/V(20.9b) * Re(10.15%) + D(6.99b)/V(20.9b) * Rd(3.23%) * (1-Tc(0.21)))
Discount Rate = 10.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.99 | Cagr: -7.63%
[DCF] Terminal Value 74.49% ; FCFF base≈1.43b ; Y1≈1.36b ; Y5≈1.29b
[DCF] Fair Price = 263.4 (EV 20.2b - Net Debt -51.6b = Equity 71.9b / Shares 272.8m; r=8.35% [WACC [floored]]; 5y FCF grow -6.63% → 2.50% )
EPS Correlation: 82.76 | EPS CAGR: 10.74% | SUE: 0.44 | # QB: 0
Revenue Correlation: 26.24 | Revenue CAGR: 2.78% | SUE: -1.48 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.88 | Chg30d=-0.51% | Revisions=+42% | Analysts=9
EPS current Year (2026-12-31): EPS=7.16 | Chg30d=-0.00% | Revisions=+27% | GrowthEPS=+26.9% | GrowthRev=+31.3%
EPS next Year (2027-12-31): EPS=9.01 | Chg30d=+0.92% | Revisions=+67% | GrowthEPS=+25.9% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +53% (up=26, down=7)